60
Participants
Start Date
July 4, 2019
Primary Completion Date
April 27, 2021
Study Completion Date
April 27, 2021
ABX464 50mg
ABX464 is a new anti-inflammatory drug
Matching Placebo
placebo matching with ABX464
ABX464 100mg
ABX464 is a new anti-inflammatory drug
Methotrexate
MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Cliniques Universitaires Saint-Luc, Brussels
UZ Gent, Ghent
UZ Leuven, Leuven
ZNA Jan Palfijn, Merksem
Fakultni Tomayerova nemocnice, Prague
Revmatologicky ustav, Prague
CHU de Brest - Hôpital Cavale Blanche, Brest
CHD Vendée, La Roche-sur-Yon
CHU de Montpellier - Lapeyronie, Montpellier
GHR Mulhouse Sud-Alsace, Mulhouse
CHU de Nice - Hôpital Pasteur, Nice
CHR d'Orléans, Orléans
APHP - Hôpital Salpétrière, Paris
CHU de Tours - Hôpital Trousseau, Tours
Complex Medical Centre - Déli Klinika, Budapest
CRU Hungary Ltd., Miskolc
CMed Rehabilitációs és Diagnosztikai Központ, Székesfehérvár
ClinicMed Daniluk, Nowak Sp. J., Bialystok
Pratia MCM, Krakow
Zespół Poradni Specjalistycznych REUMED, Lublin
NZOZ Lecznica MAK-MED S.C., Nadarzyn
Medyczne Centrum Hetmańska, Poznan
National Institute of Geriatrics, Warsaw
RHEUMA MEDICUS Zakład Opieki Zdrowotnej, Warsaw
Lead Sponsor
Abivax S.A.
INDUSTRY